bispecific small molecule

EXSCIENTIA ANNOUNCES EUR250 MILLION COLLABORATION FOR A MULTIPLE-PRODUCT DEVELOPMENT AND LICENCE OPTION AGREEMENT WITH SANOFI

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that it has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.